318 related articles for article (PubMed ID: 18608229)
1. Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome.
Joy P; Black C; Rocca A; Haas M; Wilcken B
Child Neuropsychol; 2009 Jan; 15(1):8-20. PubMed ID: 18608229
[TBL] [Abstract][Full Text] [Related]
2. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years.
Wilcken B; Haas M; Joy P; Wiley V; Bowling F; Carpenter K; Christodoulou J; Cowley D; Ellaway C; Fletcher J; Kirk EP; Lewis B; McGill J; Peters H; Pitt J; Ranieri E; Yaplito-Lee J; Boneh A
Pediatrics; 2009 Aug; 124(2):e241-8. PubMed ID: 19620191
[TBL] [Abstract][Full Text] [Related]
3. Newborn screening for medium chain acyl CoA dehydrogenase deficiency.
Leonard JV; Dezateux C
Arch Dis Child; 2009 Mar; 94(3):235-8. PubMed ID: 18838415
[TBL] [Abstract][Full Text] [Related]
4. Psychopathological manifestations of children with intellectual disabilities according to their cognitive and adaptive behavior profile.
Tremblay KN; Richer L; Lachance L; Côté A
Res Dev Disabil; 2010; 31(1):57-69. PubMed ID: 19700260
[TBL] [Abstract][Full Text] [Related]
5. Data mining methods for classification of Medium-Chain Acyl-CoA dehydrogenase deficiency (MCADD) using non-derivatized tandem MS neonatal screening data.
Van den Bulcke T; Vanden Broucke P; Van Hoof V; Wouters K; Vanden Broucke S; Smits G; Smits E; Proesmans S; Van Genechten T; Eyskens F
J Biomed Inform; 2011 Apr; 44(2):319-25. PubMed ID: 21167313
[TBL] [Abstract][Full Text] [Related]
6. Healthcare use and costs of medium-chain acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening.
Haas M; Chaplin M; Joy P; Wiley V; Black C; Wilcken B
J Pediatr; 2007 Aug; 151(2):121-6, 126.e1. PubMed ID: 17643760
[TBL] [Abstract][Full Text] [Related]
7. Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening.
Yusupov R; Finegold DN; Naylor EW; Sahai I; Waisbren S; Levy HL
Mol Genet Metab; 2010 Sep; 101(1):33-9. PubMed ID: 20580581
[TBL] [Abstract][Full Text] [Related]
8. Asperger's syndrome and autism: differences in behavior, cognition, and adaptive functioning.
Szatmari P; Archer L; Fisman S; Streiner DL; Wilson F
J Am Acad Child Adolesc Psychiatry; 1995 Dec; 34(12):1662-71. PubMed ID: 8543538
[TBL] [Abstract][Full Text] [Related]
9. MCAD deficiency in Denmark.
Andresen BS; Lund AM; Hougaard DM; Christensen E; Gahrn B; Christensen M; Bross P; Vested A; Simonsen H; Skogstrand K; Olpin S; Brandt NJ; Skovby F; Nørgaard-Pedersen B; Gregersen N
Mol Genet Metab; 2012 Jun; 106(2):175-88. PubMed ID: 22542437
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
[TBL] [Abstract][Full Text] [Related]
11. Neurodevelopmental profiles of children with very long chain acyl-CoA dehydrogenase deficiency diagnosed by newborn screening.
Brown A; Crowe L; Andresen BS; Anderson V; Boneh A
Mol Genet Metab; 2014 Dec; 113(4):278-82. PubMed ID: 25456746
[TBL] [Abstract][Full Text] [Related]
12. Enzymatic diagnosis of medium-chain acyl-CoA dehydrogenase deficiency by detecting 2-octenoyl-CoA production using high-performance liquid chromatography: a practical confirmatory test for tandem mass spectrometry newborn screening in Japan.
Tajima G; Sakura N; Yofune H; Nishimura Y; Ono H; Hasegawa Y; Hata I; Kimura M; Yamaguchi S; Shigematsu Y; Kobayashi M
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep; 823(2):122-30. PubMed ID: 16046200
[TBL] [Abstract][Full Text] [Related]
13. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study.
Wilcken B; Haas M; Joy P; Wiley V; Chaplin M; Black C; Fletcher J; McGill J; Boneh A
Lancet; 2007 Jan; 369(9555):37-42. PubMed ID: 17208640
[TBL] [Abstract][Full Text] [Related]
14. Newborn screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) in the UK.
Goddard P
J Fam Health Care; 2004; 14(4):90-2. PubMed ID: 15453442
[TBL] [Abstract][Full Text] [Related]
15. [Application of tandem mass spectrometry on the diagnosis of fatty acid oxidation disorders].
Han LS; Ye J; Qiu WJ; Gao XL; Wang Y; Zhang YJ; Gu XF
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):692-5. PubMed ID: 18067086
[TBL] [Abstract][Full Text] [Related]
16. Predictors of cognitive function and recovery 10 years after traumatic brain injury in young children.
Anderson V; Godfrey C; Rosenfeld JV; Catroppa C
Pediatrics; 2012 Feb; 129(2):e254-61. PubMed ID: 22271691
[TBL] [Abstract][Full Text] [Related]
17. The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario.
Kennedy S; Potter BK; Wilson K; Fisher L; Geraghty M; Milburn J; Chakraborty P
BMC Pediatr; 2010 Nov; 10():82. PubMed ID: 21083904
[TBL] [Abstract][Full Text] [Related]
18. Neonatal ventricular tachyarrhythmias in medium chain acyl-CoA dehydrogenase deficiency.
Yusuf K; Jirapradittha J; Amin HJ; Yu W; Hasan SU
Neonatology; 2010; 98(3):260-4. PubMed ID: 20414003
[TBL] [Abstract][Full Text] [Related]
19. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency.
Maier EM; Liebl B; Röschinger W; Nennstiel-Ratzel U; Fingerhut R; Olgemöller B; Busch U; Krone N; v Kries R; Roscher AA
Hum Mutat; 2005 May; 25(5):443-52. PubMed ID: 15832312
[TBL] [Abstract][Full Text] [Related]
20. [Neonatal screening for metabolic diseases: need for efficacy studies].
Williams M
Ned Tijdschr Geneeskd; 2008 Jul; 152(30):1653-6. PubMed ID: 18714517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
